Paclitaxel combined with trastuzumab in the treatment of operability breast cancer patients with human epidermal growth factor receptor-2 positive

VernacularTitle:紫杉醇联合曲妥珠单抗治疗表皮生长因子受体-2阳性可手术乳腺癌
Author: Hengshan LIU
Publication Type:Journal Article
Keywords: Breast neoplasms; Receptor,epidermal growth factor; Paclitaxel; Trastuzumab
From: Chinese Journal of Primary Medicine and Pharmacy 2012;19(18):2737-2738
CountryChina
Language:Chinese
Abstract: Objective To explore the effect and safety of paclitaxel combined with trastuzumab in the treatment of operability breast cancer patients with human epidermal growth factor receptor-2 positive.Methods 22 of special genetic marker,known as her2 positive invasive breast cancer patients to give the bead sheet music combined paclitaxel of every 3 new adjuvant chemotherapy treatment scheme,parallel radical surgery,and the clinical efficacy and side reactions were evaluated.Results 22 patients after treatment,13 cases complete remission,part of ease in 3cases,4 cases were stable,progress in 2 cases,the effective rate was 72.7％ ( 16/22 ),disease control rates for 90.9％(20/22) ; Richard completely ease 12 cases( 54.6％ ).Adverse reaction was mainly bone marrow inhibition and gastrointestinal reaction.Conclusion The bead sheet music combined paclitaxel of neoadjuvant chemotherapy treatment scheme special genetic marker,known as her2 positive can be the surgical treatment for breast cancer is better,and safe,has the high pathologic complete remission rate and efficient.